Number of different processes contribute to net drug absorption
Complex Delivery Routes and Generics: The Next Frontier for PBBM/PBPK Modeling
Generic drug development for locally acting drug products is a fast-growing field of interest
Data required to build a fit-for-purpose PBPK model: How much is necessary?
PBPK/PBBM model development can be initiated at any stage of product development
Predictive Dissolution Modeling with Clinically Relevant Specifications
The role of biopharmaceutics risk assessment
Simulations Plus General Overview
Our solutions inform the entire drug development process
API Enabled HTPK Deployment of Early PK Assessments for Drug Discovery
Mechanistic High-Throughput PK
Your #1 Ranked Team for Exposure and Safety Solutions!
Do you think modeling and simulation might help?
Building a Machine Learning Model for Tautomer Prediction
Many drug molecules exhibit tautomerism
AI-driven Lead Discovery
Computer based de novo drug design background
Patient-Centric Design of Long-Acting Injectable Drug Products
PBPK model description
Current status and gaps in mechanistic in-silico modeling for clinical translation and performance
Exploring mechanisms affecting in vivo dissolution of low-solubility compound crystalline suspensions
Post-Approval/Generics Track: Pushing the Boundaries Beyond – NextGen Session Panel Discussion and Live Q&A
Q&A presented at SLP MIDD+ Virtual Conference February 16th-17th, 2022
Post Approval: Generics Track – Assessing the Potential for Hepatotoxicity for Combination Therapy of Valproate (VPA) and CBD using Quantitative Systems Toxicology (QST)
Presented by Vinal Lakhani at SLP MIDD+ Virtual Conference February 16th-17th, 2022
Clinical Track: Pushing the Boundaries Beyond – NextGen Session Panel Discussion and Live Q&A
Q&A presented at SLP MIDD+ Virtual Conference February 16th-17th, 2022
Clinical Track Poster Presentation: Count data model for Alzheimer disease progression MMSE score using MonolixSuite®
Presented by Pauline Traynard at SLP MIDD+ Virtual Conference February 16th-17th, 2022
Post-Approval/Generics Track Poster Presentation: Use of PBBM to Establish Dissolution Safe Space via IVIVR for Concor®
Presented by Joyce Macwan at SLP MIDD+ Virtual Conference February 16th-17th, 2022
Post-Approval/Generics Track Poster Presentation: Relationship between Pimavanserin Exposure and QTc Interval in Patients with Schizophrenia: Modelling Analysis from Randomized, Double-Blind, Placebo-Controlled Studies
Presented by Hannah Huang at SLP MIDD+ Virtual Conference February 16th-17th, 2022
Post-Approval/Generics Track Poster Presentation: Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors. Possibilities, difficulties, and challenges
Presented by Jonathan Chauvin at SLP MIDD+ Virtual Conference February 16th-17th, 2022
Clinical Track Poster Presentation: Clinical Ocular Exposure Extrapolation Using PBPK Modeling & Simulation: Levofloxacin Solution Case Study
Presented by Maxime LeMerdy at SLP MIDD+ Virtual Conference February 16th-17th, 2022
Clinical Track: Yo-Yo Dieting Predicted to Contribute to Fibrosis Score Reductions in Untreated (Placebo) Cohorts
Presented by Lisl Shoda at SLP MIDD+ Virtual Conference February 16th-17th, 2022